Format

Send to

Choose Destination
Indian J Cancer. 2018 Jul-Sep;55(3):222-225. doi: 10.4103/ijc.IJC_622_17.

Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre.

Author information

1
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
2
Department of Anaesthesia, Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, New Delhi, India.
3
Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
4
Medical Research Officer, CSIR - Institute of Genomics and Integrative Biology, New Delhi, India.

Abstract

BACKGROUND:

Gemcitabine plus cisplatin has been established as a standard chemotherapy regimen for advanced biliary tract cancers (BTCs) based on the phase III UK ABC-02 study, which included all types of biliary cancers. There is very limited data regarding the effectiveness of known chemotherapeutic regimens especially in IHCC.

METHODS:

Records of 63 patients diagnosis of IHCC who received Gemcitabine and Carboplatin (G-C Regimen) chemotherapy as a first line were retrospectively reviewed. The primary aim of this study was to assess the response rate of gemcitabine carboplatin-based chemotherapy as a first line therapy in advanced intrahepatic cholangiocarcinoma (IHCC). The secondary objectives were to assess toxicity, progression free survival and overall survival.

RESULTS:

There were 38 men and 25 women in our study with a median age of 56.75 years (range 31-78 years). Of the 38+25= 63 patients, 21 patients (33.8%) progressed, 5 patients (8.06%) had complete response, 25 patients (40.3%) had partial response, 12 patients (19.3%) had stable disease. Overall response rate was 48.36% and tumor control rate was 67.6%. Progression free survival was 5.3 months and overall survival of 10.3 months was seen. The most common grade 3-4 toxicities were anemia, neutropenia, and thrombocytopenia. Most common nonhematological toxicity was fatigue.

CONCLUSION:

Gemcitabine in combination with carboplatin has activity against advanced IHCC. Our results are comparable with other gemcitabine carboplatin studies as well as gemcitabine cisplatin-based studies.

KEYWORDS:

Biliary cancer; chemotherapy; gemcitabine carboplatin; intrahepatic cholangiocarcinoma

PMID:
30693882
DOI:
10.4103/ijc.IJC_622_17
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center